(NASDAQ: TNGX) Tango Therapeutics's forecast annual revenue growth rate of -17.14% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 106.08%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 24.88%.
Tango Therapeutics's revenue in 2025 is $24,297,000.On average, 11 Wall Street analysts forecast TNGX's revenue for 2025 to be $5,636,332,853, with the lowest TNGX revenue forecast at $1,628,404,975, and the highest TNGX revenue forecast at $7,289,771,383. On average, 11 Wall Street analysts forecast TNGX's revenue for 2026 to be $1,947,610,624, with the lowest TNGX revenue forecast at $0, and the highest TNGX revenue forecast at $4,914,810,151.
In 2027, TNGX is forecast to generate $2,439,825,956 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $5,290,536,005.